Psychiatry Research
Volume 121, Issue 2 , Pages 109-122 , 1 December 2003

Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients

  • Prabhakar K Ranjekar

      Affiliations

    • National Chemical Laboratory, Homi Bhabha Road, Pune 411008, India
    • Interactive Research School for Health Affairs, Bharati Vidyapeeth, Pune 411043, India
    • ,
  • Ashwini Hinge

      Affiliations

    • National Chemical Laboratory, Homi Bhabha Road, Pune 411008, India
    • Interactive Research School for Health Affairs, Bharati Vidyapeeth, Pune 411043, India
    • National Center for Cell Science, Ganeshkhind Road, Pune 411007, India
    • ,
  • Mahabaleshwar V Hegde

      Affiliations

    • National Chemical Laboratory, Homi Bhabha Road, Pune 411008, India
    • Interactive Research School for Health Affairs, Bharati Vidyapeeth, Pune 411043, India
    • ,
  • Madhav Ghate

      Affiliations

    • MIMER Medical College, Talegaon, India
    • ,
  • Anvita Kale

      Affiliations

    • National Chemical Laboratory, Homi Bhabha Road, Pune 411008, India
    • Interactive Research School for Health Affairs, Bharati Vidyapeeth, Pune 411043, India
    • National Center for Cell Science, Ganeshkhind Road, Pune 411007, India
    • ,
  • Sandhya Sitasawad

      Affiliations

    • National Center for Cell Science, Ganeshkhind Road, Pune 411007, India
    • ,
  • Ulhas V Wagh

      Affiliations

    • Interactive Research School for Health Affairs, Bharati Vidyapeeth, Pune 411043, India
    • National Center for Cell Science, Ganeshkhind Road, Pune 411007, India
    • ,
  • Vijay B Debsikdar

      Affiliations

    • Kripamayee Research Center, Kripamayee Institute for Mental Health, Miraj, India
    • ,
  • Sahebarao P Mahadik

      Affiliations

    • Interactive Research School for Health Affairs, Bharati Vidyapeeth, Pune 411043, India
    • Department of Psychiatry and Health Behavior, Medical College of Georgia and Medical Research Service Line (24), VA Medical Center, 1 Freedom Way, Augusta, GA 30904-6285, USA
    • Corresponding Author InformationCorresponding author. Medical Research Service Line (24), VAMC, 1 Freedom Way, Augusta, GA 30904-6285, USA. Tel.: +1-706-733-0188x2490; fax: +1-706-823-3977

Received 5 September 2002 ,Revised 11 July 2003 ,Accepted 20 August 2003.

References 

  1. Abdalla DS, Monteiro HP, Oliveira JA, Bechara EJ. Activities of superoxide dismutase and glutathione peroxidase in schizophrenic and manic-depressive patients. Clinical Chemistry. 1986;32(5):805–807
  2. Adler LA, Peselow E, Rotrosen J, Duncan E, Lee M, Rosenthal M, et al. Vitamin E treatment of tardive dyskinesia. American Journal of Psychiatry. 1993;150:1405–1407
  3. Aebi H. Catalase in vitro. In:  Bergmeyer U editors. Third ed. Methods of Enzymatic Analysis. 3:Academic Press, New York; 1984;p. 277–281
  4. Akyol O, Herken H, Uz E, Fadillioglu E, Unal S, Sogut S, et al. The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients: the role of oxidant/antioxidant imbalance. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2002;26:995–1005
  5. American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Press; 1994;
  6. Andreasen NC, Olsen S. Negative vs. positive schizophrenia: definition and validation. Archives of General Psychiatry. 1982;39:789–794
  7. Angst J. Historical aspects of the dichotomy between manic-depressive disorders and schizophrenia. Schizophrenia Research. 2002;57:5–13
  8. Arvindakshan, M., 2003. Ph.D. Thesis: The Role of Membrane Essential Polyunsaturated Fatty Acids in Schizophrenia Outcome. Pune University Press, Pune, India
  9. Arvindakshan M, Ghate M, Ranjekar PK, Evans DR, Mahadik SP. Supplementation with a combination of omega-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia. Schizophrenia Research. 2003;62:195–204
  10. Arvindakshan M, Sitasawad S, Debsikdar V, Ghate M, Horrobin D, Bennett C, et al. Membrane essential polyunsaturated fatty acids (EPUFA) and schizophrenia outcome: EPUFA and lipid peroxide levels in never-medicated and medicated schizophrenics. Biological Psychiatry. 2003;53:56–64
  11. Cadet JL, Lohr JB. Free radicals and the developmental pathophysiology of schizophrenic burnout. Integrative Psychiatry. 1987;5:40–48
  12. Cadet JL, Perumal AS. Chronic treatment with prolixin causes oxidative stress in rat brain. Biological Psychiatry. 1990;28(8):738–740
  13. Carpenter WT, Heinrichs DW, Wagman AMI. Deficit and non-deficit forms of schizophrenia: the concept. American Journal of Psychiatry. 1988;145:578–583
  14. Christensen O, Christensen E. Fat consumption and schizophrenia. Acta Psychiatrica Scandinavica. 1988;78:587–591
  15. Crow T. The two-syndrome concept: origins and current status. Schizophrenia Bulletin. 1985;11:471–486
  16. Crow T. The continuum of psychosis and its genetic origins: the sixty-fifth Maudsley Lecture. British Journal of Psychiatry. 1990;156:788–797
  17. Crow TJ. Psychotic continuum or disease entities? The critical impact of nosology on the problem of etiology. In:  Marneros A,  Andreasen NC,  Tsuang MT editor. Psychotic Continuum. Berlin: Springer; 1995;p. 151–163
  18. Edwards, R.W., Peet, M., 1999. Essential fatty acid intake in relation to depression. In: Peet, M., Glen, I., Horrobin, D.F. (Eds.), Phospholipid Spectrum Disorders in Psychiatry. Marius Press, Lancashire, UK
  19. Evans, D.R., Parikh, V.V., Khan, M.M., Coussons, C., Buckley, P.F., Mahadik, S.P., 2003. Red blood cell membrane essential fatty acid metabolism in early psychotic patients following antipsychotic drug treatment. Prostaglandins, Leukotrienes and Essential Fatty Acids, in press
  20. Fenton WS, Hibbeln J, Knable M. Essential fatty acids, lipid membrane abnormalities and the diagnosis and treatment of schizophrenia. Biological Psychiatry. 2000;47:8–21
  21. Gershon ES, DeLisi LE, Hamovit J, Nurnberg JI, Maxwell ME, Schreiber J, et al. A controlled family study of chronic psychosis. Archives of General Psychiatry. 1988;45:328–336
  22. Glen AIM, Glen EMT, Horrobin DF, Vaddadi KS, Spellman M, Morse-Fischer N, et al. A red cell membrane abnormality in a subgroup of schizophrenic patients: evidence for two diseases. Schizophrenia Research. 1994;12:53–61
  23. Horrobin DF, Glen AI, Vaddadi K. The membrane hypothesis of schizophrenia. Schizophrenia Research. 1994;13(3):195–207
  24. Horrobin DF. The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia. Schizophrenia Research. 1998;30(3):193–208
  25. Jablensky A. Epidemiology of schizophrenia: a European perspective. Schizophrenia Bulletin. 1986;12(1):52–73
  26. Jablensky A, Häfner H. Schizophrenia and social adjustment. A prospective longitudinal study. Monogr Gesamtgeb Psychiatr Psychiatry Series. 1986;40:1–163
  27. Jablensky A, Sartorius N, Ernberg G, Anker M, Korten A, Cooper JT, et al. Schizophrenia: manifestations, incidence and course in different cultures. Psychological Medicine and Monographs Supplement. 1991;20:1–97
  28. Jeding I, Evans PJ, Akanmu D, Dexter D, Spencer JD, Aruoma OI, et al. Characterization of the potential antioxidant and pro-oxidant actions of some neuroleptic drugs. Biochemical Pharmacology. 1995;49(3):359–365
  29. Kahlbaum, K., 1963. Die Gruppirung der Psychischen Krankheiten und die Eintheilung der Seelenstorungen. AW Kafemann, Danzing
  30. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin. 1987;13(2):261–276
  31. Khan A, Khan SR, Leventhal RM, Brown WA. Symptom reduction and suicide risk among patients treated with placebo in antipsychotic clinical trials: an analysis of the Food and Drug Administration database. American Journal of Psychiatry. 2001;158:1449–1454
  32. Khan MM, Evans DR, Gunna V, Scheffer RE, Parikh VV, Mahadik SP. Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics. Schizophrenia Research. 2002;58:1–10
  33. Kirkpatrick B, Buchanan RW, Breier A, Carpenter WT. Case identification and stability of the deficit syndrome of schizophrenia. Psychiatry Research. 1993;47:47–56
  34. Kraepelin, E., 1899. Psychiatrie. Ein Lehrbuch fur Studierende und Arzte, 6th ed. Johann Ambrocius Barth, Leipzig
  35. Kuloglu M, Ustundag B, Atmaca M, Canatan H, Tezcan AE, Clinkilinc N. Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochemistry and Function. 2002;20(2):171–175
  36. Leff J, Sartorius N, Jablensky A, Korten A, Ernberg G. The International Pilot Study of Schizophrenia: five-year follow-up findings. Psychological Medicine. 1992;22(1):131–145
  37. Lohr JB, Cadet JL, Lohr MA, Larson L, Wasli E, Wade L, et al. Vitamin E in the treatment of tardive dyskinesia: the possible involvement of free radical mechanisms. Schizophrenia Bulletin. 1988;14:291–296
  38. Lohr JB, Underhill S, Moir S, Jeste DV. Increased indices of free radical activity in the cerebrospinal fluid of patients with tardive dyskinesia. Biological Psychiatry. 1990;28:535–539
  39. Maes M, Chritophe A, Delanghe J, Altamura C, Neels H, Meltzer HY. Lowered omega-3 polyunsaturated fatty acids in serum phospholipids and cholesteryl esters of depressed patients. Psychiatric Research. 1999;85:275–291
  40. Mahadik SP, Evans D. Essential fatty acids in the treatment of schizophrenia. Drugs of Today. 1997;33:5–17
  41. Mahadik SP, Evans D, Lal H. Oxidative stress and role of antioxidant and omega-3 essential fatty acid supplementation in schizophrenia. Progress in Neuropsychopharmacology and Biological Psychiatry. 2001;25(3):463–493
  42. Mahadik SP, Gowda S. Antioxidants in the treatment of schizophrenia. Drugs of Today. 1996;32:553–565
  43. Mahadik SP, Mukherjee S. Free radical pathology and antioxidant defense in schizophrenia: a review. Schizophrenia Research. 1996;19(1):1–17
  44. Mahadik SP, Scheffer RE. Oxidative injury and potential use of antioxidants in schizophrenia. Prostaglandins, Leukotrienes and Essential Fatty Acids. 1996;55:45–54
  45. Mahadik SP, Mukherjee S, Horrobin DF, Jenkins K, Correnti EE, Scheffer RE. Plasma membrane phospholipid fatty acid composition of cultured skin fibroblasts from schizophrenic patients: comparison with bipolar patients and normal controls. Psychiatry Research. 1996;63(2–3):133–142
  46. Mahadik SP, Shendarkar NS, Scheffer R, Mukherjee S, Correnti EE. Utilization of precursor essential fatty acids in culture by skin fibroblasts from schizophrenic patients and normal controls. Prostaglandins, Leukotrienes and Essential Fatty Acids. 1996;55:65–70
  47. Mahadik SP, Mukherjee S, Correnti EE, Scheffer R, Mahadik JS. Elevated plasma lipid peroxides at the onset of non-affective psychosis. Biological Psychiatry. 1998;43(9):674–679
  48. Mahadik SP, Mulchandani M, Hegde MV, Ranjekar PK. Cultural and socio–economic differences in dietary intake of essential fatty acids and antioxidants: effects on the course and outcome of schizophrenia. In:  Peet M,  Glen I,  Horrobin DF editor. Phospholipid Spectrum Disorders in Psychiatry. Lancashire, UK: Marius Press; 1999;p. 167–179
  49. Mahadik SP, Sitasawad V, Mulchandani M. Membrane peroxidation and the neuropathology of schizophrenia. In:  Peet M,  Glen I,  Horrobin DF editor. Phospholipid Spectrum Disorders in Psychiatry. Lancashire, UK: Marius Press; 1999;p. 99–111
  50. Maier W, Lichtermann D, Minges J, Hallmayer J, Heun R, Benkert O, et al. Continuity and discontinuity of affective disorders and schizophrenia: results of a controlled family study. Archives of General Psychiatry. 1993;50:871–883
  51. McCreadie RG, MacDonald E, Wiles D, Campbell G, Pateson JR. The Nithsdale Schizophrenia Surveys XIV: plasma lipid peroxide and serum vitamin E levels in patients with and without tardive dyskinesia and in normal subjects. British Journal of Psychiatry. 1995;170:1–8
  52. Mukherjee S, Mahadik SP, Scheffer R, Correnti EE, Kelkar H. Impaired antioxidant defense at the onset of psychosis. Schizophrenia Research. 1996;19(1):19–26
  53. Nemets B, Stahl Z, Belmaker RH. Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. American Journal of Psychiatry. 2002;159(3):477–479
  54. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Analytical Biochemistry. 1979;95(2):351–358
  55. Overall JE, Gorham DR. Brief Psychiatric Rating Scale. Psychological Reports. 1962;10:799–812
  56. Parikh V, Khan MM, Mahadik SP. Differential effects of antipsychotics on expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. Journal of Psychiatric Research. 2002;37:43–51
  57. Peet M, Horrobin DF. A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. Journal of Psychiatric Research. 2002;36:7–18
  58. Peet, M., Glen, I., Horrobin, D.F. (Eds), 1999. Phospholipid Spectrum Disorders in Psychiatry. Marius Press Lancashire, UK
  59. Peet M, Laugharne J, Rangarajan N, Reynolds GP. Tardive dyskinesia, lipid peroxidation and sustained amelioration with vitamin E treatment. International Clinical Psychopharmacology. 1993;8(3):151–153
  60. Ramchand CN, Davies JI, Tresman RL, Griffiths IC, Peet M. Reduced susceptibility to oxidative damage of erythrocyte membranes from medicated schizophrenic patients. Prostaglandins, Leukotrienes and Essential Fatty Acids. 1996;55(1–2):27–31
  61. Reddy R, Mahadik SP, Mukherjee S, Murthy JN. Enzymes of the antioxidant defense system in chronic schizophrenic patients. Biological Psychiatry. 1991;30(4):409–412
  62. Reddy RD, Yao JK. Free radical pathology in schizophrenia: a review. Prostaglandins, Leukotrienes and Essential Fatty Acids. 1996;55(1–2):33–43
  63. Roy D, Pathak DN, Singh R. Effects of chlorpromazine on the activities of antioxidant enzymes and lipid peroxidation in the various regions of aging rat brain. Journal of Neurochemistry. 1984;42(3):628–633
  64. Simopoulos AP. Omega-3 fatty acids in health and disease and in growth and development. American Journal of Clinical Nutrition. 1991;54(3):438–463
  65. Smythies JR. Oxidative reactions and schizophrenia: a review-discussion. Schizophrenia Research. 1997;24(3):357–364
  66. Stoklasova A, Petrakova K, Michalickova J, Zapletalek M. Activities of blood glutathione peroxidase in schizophrenic and depressive patients. Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove. 1990;33(5):501–505
  67. Stoll AL, Severus WE, Freeman MP, Rueter S, Zboyan HA, Diamond E, et al. Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Archives of General Psychiatry. 1999;56(5):407–412
  68. Subramanyam B, Pond SM, Eyles DW, Whiteford HG, Founda HG, Castagnoli N. Identification of potentially neurotoxic pyridinium metabolite in the urine of schizophrenic patients treated with haloperidol. Biochemical and Biophysical Research Communications. 1991;181(2):573–578
  69. Taylor MA. Are schizophrenia and affective disorder related? A selective literature review. American Journal of Psychiatry. 1992;149:22–32
  70. Wainwright PE. Do essential fatty acids play a role in brain and behavioral development?. Neuroscience and Biobehavioral Reviews. 1992;16:193–205
  71. Williams JB. A structured interview guide for the Hamilton Depression Rating Scale. Archives of General Psychiatry. 1988;45:742–747
  72. Yao JK, Reddy R, McElhinny LG, van Kammen DP. Effects of haloperidol on antioxidant defense system enzymes in schizophrenia. Journal of Psychiatric Research. 1998;32(6):385–391
  73. Yao JK, Leonard S, Reddy RD. Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients. Schizophrenia Research. 2000;42(1):7–17
  74. Yao JK, Reddy RD, van Kammen DP. Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications. CNS Drugs. 2001;15(4):287–310

PII: S0165-1781(03)00220-8

doi: 10.1016/S0165-1781(03)00220-8

Psychiatry Research
Volume 121, Issue 2 , Pages 109-122 , 1 December 2003

Article Tools